OBJECTIVE -The goal of this study was to estimate the health care resources spent by type 1 and type 2 diabetic patients in Spain during the year 2002.
RESEARCH DESIGN AND METHODS-This is a cost-of-illness study focusing on direct health care costs estimated from primary and secondary sources of information. A prevalence of diabetes ranging from 5 to 6% of the adult population was determined. Total cost is composed of six items: insulin and oral hypoglycemic agents, other drugs, disposable and consumable goods (glucose test strips, needles, and syringes), hospitalization, primary care visits, and visits to endocrinologists and dialysis.RESULTS -The estimated direct cost of diabetes in 2002 ranges from €2.4 to 2.67 billion. Hospital costs were the most (€933 million), followed by noninsulin, nonhypoglycemic agent drugs (€777-932 million). Much lower are the costs of insulin and oral hypoglycemic agents (€311 million), primary care visits (€181-272 million), specialized visits (€127-145 million), and disposable elements (€70 -81 million). Expenditures for all drugs and consumable goods ranged between €1.16 and 1.3 billion, representing 48 -49% of total cost, which is 15% higher than hospital costs.CONCLUSIONS -The direct health care costs of diabetic patients are high (6.3-7.4% of total National Health System expenditure). Their average annual cost is €1,290 -1,476. For individuals without diabetes, the average annual cost is €865.